Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
VANCOUVER, British Columbia and DOYLESTOWN, Pa., Sept. 13, 2016 -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that Dr. Michael J. Sofia, Arbutus’ Chief Scientific Officer, has been awarded the 2016 Lasker~DeBakey Clinical Medical Research Award for the development of a revolutionary treatment of hepatitis C virus (HCV). Dr. Sofia now leads a world class team of scientists at Arbutus that is focused on developing innovative therapies to improve cure rates in HBV.
“It is a tremendous honor to receive the Lasker~DeBakey Award for Clinical Medical Research, in recognition of the work that led to the discovery of sofosbuvir. Sofosbuvir is the backbone of HCV curative regimens which have given new hope to the 170 million HCV sufferers worldwide,” said Dr. Michael J. Sofia, Arbutus’ Chief Scientific Officer. “Now that there is a cure for HCV, I am excited to be working with my colleagues at Arbutus to develop a cure for chronic HBV infection, an unmet medical need that affects an even larger worldwide patient population.”
For 71 years, the Lasker Awards, America’s most prestigious biomedical research awards, have recognized the contributions of scientists, clinicians, and public citizens who have made major advances in the understanding, diagnosis, treatment, cure, or prevention of human disease. Recipients of the Lasker Medical Research Awards are selected by a distinguished international jury chaired by Dr. Joseph L. Goldstein, recipient of the 1985 Lasker Award for Basic Medical Research and the Nobel Prize in Physiology or Medicine. Eighty-seven Lasker laureates have received the Nobel Prize, including 41 in the last three decades.
About Arbutus
Arbutus Biopharma Corporation is a biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection. Arbutus is headquartered in Vancouver, BC, Canada with offices in Doylestown, PA, USA. For more information, visit www.arbutusbio.com.
About the Albert and Mary Lasker Foundation
Founded in 1942, the Albert and Mary Lasker Foundation envisions a healthier world through the advancement of medical research. It seeks to improve health by accelerating support for medical research through recognition of research excellence, education, and advocacy. For much of the 20th century, the Foundation was led by Mary Lasker, who was America's most prominent citizen-activist for public investment in medical research. She is widely credited with motivating the White House and Congress to greatly expand federal funding for medical research, particularly through the NIH. For more information on the Lasker Award recipients, the full citations for each award category, video interviews and photos of the awardees, and additional information on the Foundation please refer to www.laskerfoundation.org.
Contact Information Investors Adam Cutler Senior Vice President, Corporate Affairs Phone: 604.419.3200 Email: [email protected] Helia Baradarani Senior Manager, Investor Relations Phone: 604.419.3200 Email: [email protected] Media Please direct all media inquiries to: [email protected]
